THE VALUED VOICE

Vol. 64, Issue 28
Click here to view past issues
Thursday, July 9, 2020

   

State’s DHS Moving to New Phase of Remdesivir Distribution

As directed by the U.S. Department of Health and Human Services (HHS), the State of Wisconsin is moving into a new phase of Remdesivir distribution as early as next week. Currently, the Wisconsin Department of Health Services (DHS) receives a weekly allocation from HHS and distributes that supply based on requests that hospitals submit. The supply is distributed to hospitals free-of-charge. Going forward the state will continue to allocate Remdesivir, but hospitals will be invoiced by the Remdesivir distributor, AmerisourceBergen. When indicating a desire to receive a Remdesivir distribution you are also agreeing to pay for the drug you receive.
 
This Fact Sheet from HHS provides more detail, including the cost of Remdesivir; hospitals will pay no more than the wholesale acquisition cost (WAC) set by Gilead, which amounts to approximately $3,200 per treatment course.
 
For more information, contact dhsoperations@dhs.wisconsin.gov, a special email account multiple DHS staff monitor.

This story originally appeared in the July 09, 2020 edition of WHA Newsletter

WHA Logo
Thursday, July 9, 2020

State’s DHS Moving to New Phase of Remdesivir Distribution

As directed by the U.S. Department of Health and Human Services (HHS), the State of Wisconsin is moving into a new phase of Remdesivir distribution as early as next week. Currently, the Wisconsin Department of Health Services (DHS) receives a weekly allocation from HHS and distributes that supply based on requests that hospitals submit. The supply is distributed to hospitals free-of-charge. Going forward the state will continue to allocate Remdesivir, but hospitals will be invoiced by the Remdesivir distributor, AmerisourceBergen. When indicating a desire to receive a Remdesivir distribution you are also agreeing to pay for the drug you receive.
 
This Fact Sheet from HHS provides more detail, including the cost of Remdesivir; hospitals will pay no more than the wholesale acquisition cost (WAC) set by Gilead, which amounts to approximately $3,200 per treatment course.
 
For more information, contact dhsoperations@dhs.wisconsin.gov, a special email account multiple DHS staff monitor.

This story originally appeared in the July 09, 2020 edition of WHA Newsletter

Other Articles in this Issue